Candel Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $608.62M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | $-0.52 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | $-0.14 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | Before market open | – | $-0.54 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-0.21 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $0.13 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | After market close | – | $-0.40 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | $-0.74 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | $0 | – | – |
Press releases
Announcements Candel Therapeutics filed with the SEC
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
cancer NASDAQ: CADL Corporate Presentation | September 2026 © © 2026 2026 by by C Ca an ndel del T Ther hera ap peu eut ti ic cs s
Regulation FD disclosure · EX-99.1 to Form 8-K
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
AUA Investor Call Extended Data from
Regulation FD disclosure · EX-99.1 to Form 8-K
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of
Regulation FD disclosure · EX-99.2 to Form 8-K
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Candel Therapeutics Announces Proposed $100 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Announces Pricing of Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
cancer Corporate Presentation | March 2025 NASDAQ: CADL
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Announces $80 Million Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Announces Pricing of Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Candel Therapeutics Announces CAN-2409 Achieved Primary
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Top-line Data th Wednesday, December 11 , 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virus Conference (IOVC)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Candel Therapeutics Announces Upcoming Presentations
Regulation FD disclosure · EX-99.1 to Form 8-K
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K